Oral alitretinoin treatment in patients with palmoplantar pustulosis inadequately responding to standard topical treatment: a randomized phase II study

The British Journal of Dermatology
Kristian ReichN Mehta

Abstract

Palmoplantar pustulosis (PPP) is an inflammatory, debilitating skin disease. Topical drugs and systemic immunosuppressive agents are often ineffective. Previous uncontrolled studies have suggested that alitretinoin could be a meaningful treatment option for PPP. The primary objective was to determine response to alitretinoin for the treatment of PPP based on the Palmoplantar Pustulosis Area and Severity Index (PPPASI) after 24 weeks of treatment. A phase II, randomized, double-blind, placebo-controlled, multicentre study. Adult patients with PPP (with or without psoriasis) refractory to topical therapy and standard skin care were randomized 2:1 to alitretinoin 30 mg once daily or placebo for up to 24 weeks. The primary end point was PPPASI at week 24 (or the last visit in case of early withdrawal). Secondary end points included: percentage change from baseline in the modified Psoriasis Area and Severity Index (mPASI); percentage of patients with ≥ 50% or 75% improvement in PPPASI or mPASI scores from baseline; change in pustule count on the palms and soles; change in the Nail Psoriasis Severity Index and safety and tolerability assessments. Thirty-three patients were randomized: 24 patients to alitretinoin 30 mg and nine to pla...Continue Reading

References

Dec 1, 1988·The British Journal of Dermatology·A Lassus, J M Geiger
Feb 1, 1984·The British Journal of Dermatology·C M LawrenceS Shuster
Nov 13, 2001·International Journal of Dermatology·K Ettler, B Richards
Mar 22, 2003·The Journal of Investigative Dermatology·Kati AsumalahtiJonathan N W N Barker
Sep 13, 2008·Seminars in Cutaneous Medicine and Surgery·Megan Brelsford, Trisha Clarke Beute
May 27, 2009·Journal of the American Academy of Dermatology·Elizabeth FarleyAlan Menter
May 28, 2009·Journal of the European Academy of Dermatology and Venereology : JEADV·E AdişenM A Gürer
Apr 29, 2010·The British Journal of Dermatology·A D OrmerodUNKNOWN BAD Clinical Standards Unit
May 15, 2010·Journal of the European Academy of Dermatology and Venereology : JEADV·Robert BissonnetteHoward I Maibach
Aug 7, 2010·The Journal of Dermatological Treatment·Anne C de Waal, Peter C M van de Kerkhof
Feb 1, 2011·The British Journal of Dermatology·U Mrowietz, P C M van de Kerkhof
May 23, 2012·The British Journal of Dermatology·N IrlaN Yawalkar

❮ Previous
Next ❯

Citations

Jun 1, 2016·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·P WeisenseelR Mössner
Apr 23, 2017·The Journal of Dermatology·Min-Young ParkHyun-Chang Ko
Jul 22, 2017·The British Journal of Dermatology·J AlbrechtJ M Batchelor
Aug 16, 2016·Journal of the European Academy of Dermatology and Venereology : JEADV·M Misiak-GalazkaL Rudnicka
May 20, 2016·Experimental Dermatology·Natalie Garzorz-StarkKilian Eyerich
Jan 21, 2020·The Cochrane Database of Systematic Reviews·Grace ObeidLaurence Le Cleach
Feb 3, 2020·American Journal of Clinical Dermatology·Magdalena Misiak-GalazkaLidia Rudnicka
Apr 27, 2017·The British Journal of Dermatology·A M G Brunasso, C Massone
Jan 12, 2019·Clinical Drug Investigation·Toshiyuki Yamamoto
Sep 5, 2020·Clinical, Cosmetic and Investigational Dermatology·Egídio FreitasTiago Torres
Jan 18, 2021·International Journal of Dermatology·Noriko KatoDaisuke Watanabe
Nov 14, 2020·Medicina·Bo Young ChungHye One Kim

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.